Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning, all! Today, we hear an optimistic view of the biotech IPO market next year, note a few key FDA issues to watch in 2026, see an interesting Trump deal that asks companies to trade active pharmaceutical ingredients to relieve tariff pressures, and more.
The need-to-know this morning
- AstraZeneca announced that a new Imfinzi combination failed to extend the lives of lung cancer patients. It also licensed a new KRAS inhibitor out of China for $100 million.
VC Bruce Booth: IPO window poised to reopen
After two years of near stasis in the biotech IPO market, Atlas Venture partner Bruce Booth predicts a surge of new public offerings in 2026. He thinks there will be a sharp rebound in biotech stock performance and investors will have a renewed appetite for risk.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
